NASDAQ$BCRX
BioCryst Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
BioCryst announced financial results for the first quarter ended March 31, 2021, and provided a corporate update.
BioCryst's Q1 2021 total revenues were $19.1 million, primarily driven by $10.9 million in ORLADEYO net revenue. The company's net loss was $64.3 million, or $0.36 per share. Cash, cash equivalents, restricted cash and investments totaled $244.4 million at March 31, 2021.
- ORLADEYO net revenue reached $10.9 million in Q1 2021.
- ORLADEYO is now approved in the U.S., Japan, and EU.
- Agreement reached with FDA on hemoglobin change as primary endpoint for pivotal PNH trials of oral BCX9930.
- PNH trials of oral BCX9930 are set to begin in the second half of 2021.
Headline financials
Revenue & EPS history
BioCryst · Revenue · Quarterly
$19.1M
Forward guidance
BioCryst is not providing specific revenue or operating expense guidance for the launch period of ORLADEYO. The company believes its current cash runway extends into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.3%
Avg return
Earnings day
+3.1%
Avg return
5 days after
+5.6%
Avg return
30 days after
41%
26 / 64 earnings
Positive
+26.0%
Q2 2022
Best reaction
-38.0%
Q3 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -5.0% | -7.0% | |
| Q4 2025 | +4.8% | +15.1% | +23.6% | |
| Q3 2025 | -5.4% | -3.1% | +7.2% | |
| Q1 2025 | +23.7% | +11.6% | +23.6% | |
| Q4 2024 | -10.0% | -6.5% | -15.3% | |
| Q3 2024 | -16.3% | -7.7% | -13.0% | |
| Q2 2024 | +12.1% | +8.7% | +17.9% | |
| Q1 2024 | +18.2% | +19.6% | +52.6% | |
| Q4 2023 | +2.8% | -1.6% | -9.8% | |
| Q3 2023 | +5.4% | +5.9% | +7.3% | |
| Q2 2023 | +9.4% | +1.0% | +4.7% | |
| Q1 2023 | +14.9% | +15.2% | +13.3% | |
| Q4 2022 | -4.2% | -10.8% | -20.4% | |
| Q3 2022 | -10.0% | -6.8% | -2.9% | |
| Q2 2022 | +26.0% | +29.6% | +26.2% | |
| Q1 2022 | -10.7% | -15.5% | +2.7% | |
| Q4 2021 | -6.0% | -6.4% | -9.9% | |
| Q3 2021 | -23.3% | -19.3% | -24.4% | |
| Q2 2021 | +8.3% | -6.5% | -3.7% | |
| Q1 2021 | +22.8% | +13.7% | +52.5% | |
| Q4 2020 | -8.7% | -0.6% | -12.4% | |
| Q3 2020 | -4.4% | -4.4% | +42.9% | |
| Q2 2020 | -5.7% | -5.9% | -13.1% | |
| Q1 2020 | -0.8% | +40.3% | +5.6% | |
| Q4 2019 | +17.1% | -19.9% | -44.4% | |
| Q3 2019 | +1.5% | -5.9% | +31.5% | |
| Q2 2019 | -2.1% | -0.4% | +10.6% | |
| Q1 2019 | +1.7% | -1.0% | -54.0% | |
| Q4 2018 | -3.0% | -7.5% | +0.2% | |
| Q3 2018 | +0.8% | -2.9% | +12.9% | |
| Q2 2018 | +9.2% | +24.8% | +31.1% | |
| Q1 2018 | -4.1% | -1.1% | +10.4% | |
| Q4 2017 | -1.6% | -0.4% | -5.5% | |
| Q3 2017 | -3.1% | -0.6% | -5.8% | |
| Q2 2017 | -12.0% | -11.2% | -2.7% | |
| Q1 2017 | -12.4% | -13.4% | -14.7% | |
| Q4 2016 | +13.7% | +39.9% | +54.6% | |
| Q3 2016 | +19.4% | +36.6% | +40.9% | |
| Q2 2016 | +2.7% | +22.8% | +4.2% | |
| Q1 2016 | -5.3% | — | — | |
| Q4 2015 | -12.0% | — | — | |
| Q3 2015 | -7.6% | — | — | |
| Q2 2015 | -14.1% | — | — | |
| Q1 2015 | +9.2% | — | — | |
| Q4 2014 | -0.1% | — | — | |
| Q3 2014 | +8.1% | — | — | |
| Q2 2014 | -1.4% | — | — | |
| Q1 2014 | +4.6% | — | — | |
| Q4 2013 | -6.0% | — | — | |
| Q3 2013 | +13.2% | — | — | |
| Q2 2013 | -9.1% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | -1.6% | — | — | |
| Q3 2012 | -38.0% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | -0.5% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q3 2011 | -2.0% | — | — | |
| Q2 2011 | -18.0% | — | — | |
| Q1 2011 | +3.0% | — | — | |
| Q4 2010 | -2.6% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q2 2010 | -5.1% | — | — | |
| Q1 2010 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro